Presence of Tumour and Higher Levels of LAG3-positive T-cells in the Blood May Be Necessary to Derive Clinical Benefit with Nivolumab Plus Relatlimab Over Nivolumab in Melanoma By Ogkologos - November 11, 2025 228 0 Facebook Twitter Google+ Pinterest WhatsApp Primary results of RELATIVITY-098 and translational evidence from RELATIVITY-098 and RELATIVITY-047 studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Associations Between Genomic Features and Response to Neoadjuvant Treatment in a... August 30, 2022 Early Signs of Efficacy of New Targeted Agents and Immunotherapies Reported... September 24, 2021 EMA Recommends Extension of Therapeutic Indications for Acalabrutinib June 18, 2025 Survivorship and Immune Checkpoint Inhibitors July 21, 2020 Load more HOT NEWS Many Men with Metastatic Prostate Cancer Are Not Getting the Recommended... New Class of Compounds Rewires Cancer Cells to Self-Destruct Study Identifies Hundreds of Potential Targets for Cancer Drugs 2020 Cancer Incidence and Mortality in EU-27 Countries
